Takeda Pharmaceuticals USA

Akorn Inc is a pharmaceutical company based in Ann Arbor, MI, specializing in the development and manufacturing of generic and branded prescription drugs. The company focuses on providing affordable and accessible healthcare solutions to patients worldwide. With a commitment to quality and innovation, Akorn Inc works diligently to meet the needs of healthcare professionals and patients by delivering a wide range of pharmaceutical products across various therapeutic areas. The company's dedication to excellence in research and development ensures the continued growth and success of its operations in the pharmaceutical industry. Generated from their business information

NanoBio Corporation is a biopharmaceutical company that specializes in the development and commercialization of topical and mucosal antimicrobial products. These products are derived from its patented NanoStat technology platform. The company s antimicrobial nanomulsions are water/oil emulsions that employ uniformly sized droplets in the nanometer range. NanoStat destroys microbes effectively without toxicity or harmful residual effects. The technology is effective against bacteria, viruses, fungi and spores. The antimicrobial nanoemulsions have shown effectiveness in viral respiratory infection prevention. Laboratory results with mice indicate that exposure to pathogens after treatment of their nares with nanoemulsion offers protection against pathogen challenge and can induce protective pathogenic immunity in the absence of an active infection. NanoBio Corporation is based in Ann Arbor, Mich.

BlueWillow Biologics, based in Ann Arbor, MI, is a pioneering company at the forefront of developing next-generation mucosal vaccines. Their clinical-stage intranasal adjuvanted antigen delivery platform utilizes oil-in-water emulsion technology to elicit a balanced mucosal, cellular, and systemic immune response for robust and durable protection. With a focus on human safety and compatibility with a broad range of antigens, BlueWillow's innovative technology has shown promising results in various clinical trials, including protection in hamsters, induction of immunity in mice, and positive interim data for vaccines against Covid-19 and anthrax. Their advancements in intranasal vaccination and immunotherapy mark them as a leader in the field of mucosal vaccine development.Generated from the website